Routes of
administration Oral Legal status Investigational PubChem CID 9829523 | ATC code L01XE39 (WHO) CAS Number 120685-11-2 Molar mass 570.637 g/mol | |
 | ||
Synonyms 4'-N-benzoylstaurosporine | ||
Dr steensma on midostaurin for patients with aml
Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor, FLT3).
Contents
- Dr steensma on midostaurin for patients with aml
- The efficacy of midostaurin in subsets of aml
- References
After successful Phase II clinical trials, a Phase III trial for AML has started in 2008. It is testing midostaurin in combination with daunorubicin and cytarabine. In another trial, the substance has proven ineffective in metastatic melanoma.
In an open-label study of patients with mastocytosis-related organ damage (89 eligible patients meeting inclusion for the primary efficacy population), midostaurin showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal variant mast-cell leukemia.